DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett’s Esophagus/Esophageal Adenocarcinoma
Condition(s):Barrett’s Esophagus; Esophageal AdenocarcinomaLast Updated:March 6, 2020Completed
Hide Studies Not Open or Pending
Condition(s):Barrett’s Esophagus; Esophageal AdenocarcinomaLast Updated:March 6, 2020Completed
Condition(s):Submucosal Esophageal Adenocarcinoma; Barrett Esophagus; High-risk Mucosal Esophageal AdenocarcinomaLast Updated:January 14, 2021Recruiting
Condition(s):Esophageal AdenocarcinomaLast Updated:May 31, 2023Active, not recruiting
Condition(s):Esophagus AdenocarcinomaLast Updated:November 27, 2023Recruiting
Condition(s):Esophageal AdenocarcinomaLast Updated:April 13, 2017Completed
Condition(s):Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)Last Updated:July 28, 2023Terminated
Condition(s):Esophageal Adenocarcinoma; Oesophageal Adenocarcinoma; Resectable CarcinomaLast Updated:December 19, 2022Active, not recruiting
Condition(s):Esophageal AdenocarcinomaLast Updated:November 22, 2023Recruiting
Condition(s):Esophageal NeoplasmsLast Updated:July 13, 2023Recruiting
Condition(s):Barrett Esophagus; Esophageal AdenocarcinomaLast Updated:November 2, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.